Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

RSS icon
Transcatheter mitral valve repair (TMVr) is associated with “promising” short-term outcomes among patients with a history of cancer, according to new research published in the American Journal of Cardiology.

MitraClip and TriClip TEER devices continue to show positive results

Two late-breaking studies at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) meeting provided positive data for Abbott's MitraClip transcatheter mitral valve repair (TMVR) device and the TriClip for transcatheter tricuspid valve repair (TTVR).

The Pulnovo pulmonary artery denervation catheter. In February 2021, the devices was granted the U.S. Food and Drug Administration (FDA) breakthrough device designation. #TCT2022 #PAH

Pulmonary artery denervation shows promise to treat pulmonary arterial hypertension

Pulmonary artery denervation may offer a new therapy option for this difficult-to-treat population.

The Pascal transcatheter mitral valve repair system. Similar to the latest version of the MitraClip, the Pascal can operate each leaflet independently to grasp the mitral valve leaflets. Results of the CLASP IID trial at #TCT2022.

Pascal transcatheter mitral repair device performs as well as MitraClip in late-breaking CLASP IID Trial 

Comparison between transcatheter edge-to-edge repair (TEER) devices found Pascal was non-inferior compared with MitraClip in the CLASP IID pivotal trial.

Use of ultrasound to guide needles used for femoral vascular access for cath lab procedures can help reduce bleeding and vascular complications. But the Universal Trial at TCT 2022 showed no difference. Image courtesy of Sonosite

Ultrasound guidance for femoral access did not reduce bleeding or vascular complications in TCT late-breaker

The UNIVERSAL Trial, one of the largest multicenter randomized trials comparing ultrasound with fluoroscopic guidance vs. fluoroscopic guidance alone, found there was no reduction in major vascular access complications. 

Positive data was presented on the first-generation Symplicity (left) long-term outcomes and from the Recor ultrasound renal denervation system pivotal trial at TCT 2022. #TCT #TCT2022

Renal denervation lowered blood pressure in two late-breaking TCT trials 

Results from the Medtronic SYMPLICITY HTN-3 trial long-term results and the pivotal RADIANCE II trial for the Recor ultrasound renal denervation system lowered blood pressure effectively in drug-resistant patients.

Sentinel Boston Scientific PROTECTED TAVR stroke disabling stroke

TAVR embolic protection devices fail to reduce stroke risk, but some cardiologists—and a leading vendor—remain encouraged

The PROTECTED TAVR results presented at TCT 2022 resulted in a mix of reactions. For some cardiologists, the slight reduction in the risk of a disabling stroke after TAVR is a positive result. For others, it was simply not enough. 

TCT 2022 Robert Califf FDA Commissioner

FDA Commissioner Robert Califf delivers fiery speech on innovation, healthcare disparities and misinformation at TCT 2022

“The United States is essentially inventing the technology and then the rest of the world is figuring out how to use it better,” he said.

he U.S. Food and Drug Administration (FDA) granted market clearance ion September 2022 for the Edwards Lifesciences Corp. Pascal Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER). It is indicated for the treatment of patients with degenerative mitral regurgitation (DMR).

FDA clears Edwards Pascal device for transcatheter mitral valve repair

This is the second FDA-cleared transcatheter repair device for the mitral valve. Data from pivotal trial comparing Pascal vs. MitraClip will be presented at TCT 2022.

Displaying 41 - 48 of 104

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

 

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup